Liontrust UK Opportunities Fund on Creo Medical Group plc
Thesis
Liontrust continues to hold Creo Medical following earlier revenue momentum and an announced disposal of the remaining 49% stake in its European distribution business. The stock surrendered previous gains when completion of the transaction moved into the fourth quarter. The managers remain confident the sale will conclude in the coming months. The resulting near-term catalyst is completion of the previously announced divestment, alongside the operating momentum already cited.
“We remain confident that the deal will conclude over the coming months.”
Key risks
- Completion of the European distribution disposal has already been delayed into the fourth quarter.
- Further delays could keep the expected transaction catalyst from being realised.